{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Cohort+3%29&page=23", "query": { "intervention": "Placebo (Cohort 3)", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 1069, "total_pages": 107, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Cohort+3%29&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Cohort+3%29&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T03:46:34.294Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05844293", "title": "Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "FXI" ], "interventions": [ { "name": "FXI-GalNAc-siRNA", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Sirnaomics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 40, "start_date": "2023-05-16", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-15T03:46:34.294Z", "location_count": 1, "location_summary": "Creve Coeur, Missouri", "locations": [ { "city": "Creve Coeur", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05844293" }, { "nct_id": "NCT06372249", "title": "A Clinical Trial of Soluble Fiber for Asthma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma in Children" ], "interventions": [ { "name": "Inulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Phoenix Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 105, "start_date": "2025-11-10", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-10-15T03:46:34.294Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06372249" }, { "nct_id": "NCT01401985", "title": "A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Opioid Induced Constipation" ], "interventions": [ { "name": "TD-1211", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glycyx Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 95, "start_date": "2011-10", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-15T03:46:34.294Z", "location_count": 1, "location_summary": "Pasadena, California", "locations": [ { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01401985" }, { "nct_id": "NCT04915755", "title": "Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2021-06-28", "completion_date": "2025-12-31", "has_results": true, "last_update_posted_date": "2025-07-16", "last_synced_at": "2026-10-15T03:46:34.294Z", "location_count": 24, "location_summary": "Burbank, California • Duarte, California • Palo Alto, California + 20 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04915755" }, { "nct_id": "NCT04315298", "title": "Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Sarilumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1912, "start_date": "2020-03-18", "completion_date": "2020-09-02", "has_results": true, "last_update_posted_date": "2021-09-23", "last_synced_at": "2026-10-15T03:46:34.294Z", "location_count": 62, "location_summary": "Los Angeles, California • Sacramento, California • Santa Monica, California + 42 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04315298" }, { "nct_id": "NCT07549581", "title": "A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia", "Major Depressive Disorder (MDD)", "Bipolar Disorder" ], "interventions": [ { "name": "SEP-380135", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 43, "start_date": "2024-11-07", "completion_date": "2025-09-12", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-10-15T03:46:34.294Z", "location_count": 1, "location_summary": "Los Alamitos, California", "locations": [ { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07549581" }, { "nct_id": "NCT04090411", "title": "A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Moderate to Severe Ulcerative Colitis" ], "interventions": [ { "name": "Induction- PF-06480605 50 mg SC Q4W", "type": "DRUG" }, { "name": "Induction- PF-06480605 150 mg SC Q4W", "type": "DRUG" }, { "name": "Induction- PF-06480605 450 mg SC Q4W", "type": "DRUG" }, { "name": "Induction- Placebo SC Q4W", "type": "OTHER" }, { "name": "Chronic- PF-06480605 50 mg SC Q4W", "type": "DRUG" }, { "name": "Chronic- PF-06480605 150 mg SC Q4W", "type": "DRUG" }, { "name": "Chronic- PF-06480605 450 mg SC Q4W", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 246, "start_date": "2019-12-19", "completion_date": "2022-10-25", "has_results": true, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-15T03:46:34.294Z", "location_count": 55, "location_summary": "Dothan, Alabama • Little Rock, Arkansas • Newport Beach, California + 20 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04090411" }, { "nct_id": "NCT06693843", "title": "A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity, Overweight, or Chronic Weight Management" ], "interventions": [ { "name": "Aleniglipron or Placebo", "type": "DRUG" }, { "name": "Aleniglipron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 230, "start_date": "2024-10-28", "completion_date": "2026-07-09", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-15T03:46:34.294Z", "location_count": 39, "location_summary": "Phoenix, Arizona • Anaheim, California • Los Angeles, California + 33 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Montclair", "state": "California" }, { "city": "Rancho Cucamonga", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06693843" }, { "nct_id": "NCT03844191", "title": "A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Coronary Disease" ], "interventions": [ { "name": "RUC-4 Compound", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CeleCor Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 44, "start_date": "2019-02-18", "completion_date": "2019-12-01", "has_results": false, "last_update_posted_date": "2024-08-27", "last_synced_at": "2026-10-15T03:46:34.294Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03844191" }, { "nct_id": "NCT01466374", "title": "Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "BMS-936557 (Anti-IP-10 Antibody)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 121, "start_date": "2011-12", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2015-10-12", "last_synced_at": "2026-10-15T03:46:34.294Z", "location_count": 10, "location_summary": "Santa Monica, California • Winter Park, Florida • Hammond, Louisiana + 7 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Winter Park", "state": "Florida" }, { "city": "Hammond", "state": "Louisiana" }, { "city": "Chevy Chase", "state": "Maryland" }, { "city": "Lees Summit", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01466374" } ] }